Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Crinetics Pharmaceuticals, Inc. (CRNX)

84.95 0.00 (0.00%)
At close: August 31 at 4:00:00 PM EDT
Trade CRNX on Coinbase
View in AlphaSpace Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Total Revenue
42,156
7,696
1,039
4,013
4,737
Cost of Revenue
1,430
1,076
0
0
--
Gross Profit
40,726
6,620
1,039
4,013
--
Operating Expense
589,815
523,389
339,893
226,621
172,619
Operating Income
-549,089
-516,769
-338,854
-222,608
-167,882
Net Non Operating Interest Income Expense
48,391
51,989
41,435
13,436
4,317
Other Income Expense
-728
-357
-989
-5,357
-353
Pretax Income
-501,426
-465,137
-298,408
-214,529
-163,918
Tax Provision
--
180
0
0
--
Net Income Common Stockholders
-501,606
-465,317
-298,408
-214,529
-163,918
Diluted NI Available to Com Stockholders
-501,606
-465,317
-298,408
-214,529
-163,918
Basic EPS
-5.05
-4.95
-3.69
-3.69
-3.15
Diluted EPS
-5.05
-4.95
-3.69
-3.69
-3.15
Basic Average Shares
99,750
94,057
80,783
58,071
51,982
Diluted Average Shares
99,750
94,057
80,783
58,071
51,982
Total Operating Income as Reported
-549,089
-516,769
-338,854
-222,608
-167,882
Total Expenses
591,245
524,465
339,893
226,621
172,619
Net Income from Continuing & Discontinued Operation
-501,606
-465,317
-298,408
-214,529
-163,918
Normalized Income
-501,606
-465,317
-298,408
-214,529
-164,518
Interest Income
48,391
51,989
41,435
13,436
4,317
Net Interest Income
48,391
51,989
41,435
13,436
4,317
EBIT
-549,089
-516,769
-338,854
-222,608
-167,882
EBITDA
-544,850
-512,879
-336,069
-221,510
-166,899
Reconciled Cost of Revenue
1,430
1,076
0
0
--
Reconciled Depreciation
4,239
3,890
2,785
1,098
983
Net Income from Continuing Operation Net Minority Interest
-501,606
-465,317
-298,408
-214,529
-163,918
Total Unusual Items Excluding Goodwill
--
--
--
--
600
Total Unusual Items
--
--
--
--
600
Normalized EBITDA
-544,850
-512,879
-336,069
-221,510
-167,499
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2022 - 7/18/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: